92 results about "Mucosal immunity" patented technology

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention provides lactobacillus gasseri which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.26504. The lactobacillus gasseri has the advantages that the lactobacillus gasseri can be used for preparing the lactobacillus gasseri; the lactobacillus gasseri has a relatively strong inhibition effect on pathogenic bacteria such as Gardneria vaginalis, Escherichia coli, staphylococcus aureus and two-way Pleuromycosis, and also has a certain inhibition effect on CA, so that the lactobacillus gasseri has the effects of killing pathogenic bacteria, improving the host mucosal immunity and resisting infection, and has a good application prospect in the field of animal husbandry, animal husbandry, animal husbandry, animal husbandry, animal husbandry, animal husbandry, animal husbandry and animal husbandry. Meanwhile, growth and reproduction of harmful bacteria can be inhibited, vaginal infection is prevented, and inflammation is treated.

The invention relates to the technical field of biological genetic engineering, in particular to construction of recombinant lactobacillus plantarum of an African swine fever virus antigen, and the method comprises the following steps: constructing a lactobacillus plantarum shuttle vector containing different ASFV antigen genes; and referring to a genome sequence of a Chinese isolate CADCHN09 of ASFV disclosed in GenBank. The method has the advantages that an inducer is not needed, antigen protein is efficiently expressed, the dendritic cell (DC) binding peptide for enhancing immune cell uptake and processing is subjected to fusion expression, the oral immunization mode is simple, mucosal immunity is stimulated, and ASFV infection is effectively prevented and controlled; probiotics, namely lactobacillus plantarum, which naturally exist in animal intestinal tracts and can be colonized and copied in digestive tracts for a long time are used as a carrier; key epitopes of proteins such as nucleocapsid protein p72, outer envelope protein CD2v, inner envelope protein p54, p22, pE199L and pE248R, which play an important role in adsorption, internalization, endocytosis and membrane fusion of ASFV, are preferably fused with dendritic cell binding peptide and then are displayed on the surface of lactobacillus plantarum.

The present invention concerns isolated human breast milk exosomes, and compositions thereof, and uses of said exosomes and compositions for promoting immunity and treating and / or preventing mucosal immunity and inflammation.

The invention relates to the technical field of veterinary biological products. The invention provides a poultry epidemic disease inactivated vaccine adjuvant as well as a preparation method and application thereof. The adjuvant is prepared from the following raw materials in dosage ratio: 70 to 80mL of white oil, 0.5 to 1.5 mL of Tween-80, 1 to 2g of chitosan, 0.5 to 1.5 g of astragalus polysaccharide and 0.5 to 1.5 g of vitamin E. According to the invention, multiple raw materials are utilized, and a triple synergistic mechanism of long-acting slow release, efficient activation and safety protection is formed through emulsion stabilization and targeted delivery at a physical level, multi-channel activation (including natural immunity, adaptive immunity, humoral immunity and mucosal immunity) at an immune level and synergistic oxidation resistance and inflammatory reaction regulation at a safety level; the immune response efficiency, the antibody duration and the safety of the vaccine can be remarkably improved, and the vaccine is particularly suitable for the special immune physiological characteristics of poultry.

The invention discloses a multi-target intervention-based plant compound gynecological anti-HPV (human papillomavirus) gel preparation, which comprises two parts, namely a compound plant extracting solution and an aqueous gel carrier, the compound extracting solution is derived from rheum officinale, scutellaria baicalensis, coptis chinensis, golden cypress, radix sophorae flavescentis, fructus cnidii, alum, gallnut, common carpesium fruit, radix angelicae, cortex dictamni, fructus kochiae, frankincense and myrrh; the anti-HPV gel preparation is obtained by mixing and stirring according to the proportion. Aiming at an intervention window that a patient is continuously infected but does not deteriorate to an operation stage, intervention is carried out by adopting an action mechanism of local epithelial micro-ecological restoration and mucosal immunity, E6 / E7 oncogenic protein expression is inhibited, L1 capsid assembly is damaged, key nodes of a virus life cycle are covered, and escape risks are reduced by multi-target collaborative anti-HPV (Human Papilloma Virus); by inhibiting an NF-kB / EMT signal axis, the cervical lesion progress risk is reduced; the safety is high and the curative effect is obvious.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The invention discloses an influenza virus nano vaccine as well as a preparation method and application thereof. The invention relates to the field of biomedicine, and provides an influenza virus nano vaccine, which comprises nano particles and an STING agonist adsorbed on the surfaces of the nano particles, the nanoparticle comprises a polysaccharide antigen conjugate and a dendritic macromolecule, wherein the polysaccharide antigen conjugate is formed by coupling beta-glucan and influenza virus antigen protein, and the dendritic macromolecule and the polysaccharide antigen conjugate are adsorbed together. The immune response induced by the vaccine is higher than that of monomer immunogen protein without the adjuvant, body fluid, cell and mucosa immune response can be remarkably activated, lethal attack of an organism to H1N1 and H5N1 viruses can be effectively protected through nasal spray inoculation, and the nano vaccine can stimulate cross immune response and immune protection effect to different subtype influenza viruses.

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

The invention relates to a self-adjuvant based on a virus source glycopeptide and an application of the self-adjuvant in preparation of a vaccine, the self-adjuvant is a glycopeptide fragment based on a varicella-zoster virus (VZV) source, and the self-adjuvant is a B cell epitope structural domain V50 glycopeptide (from 50 valine to 135 isoleucine, V50-I135) in glycoprotein E. The invention further relates to a preparation method of the self-adjuvant based on the virus source glycopeptide and application of the self-adjuvant based on the virus source glycopeptide in preparation of the vaccine. The V50 glycopeptide and the novel coronavirus RBD are subjected to fusion expression and then are coupled to the surfaces of the nanoparticles based on ferritin to form the self-adjuvant vaccine, so that the levels of RBD specific antibodies and pseudovirus neutralizing antibodies induced by the RBD nanoparticle vaccine can be remarkably enhanced, and the V50 glycopeptide has a synergistic effect in B cell response and T cell response of systemic systemic immunity and mucosal immunity at the same time. The immune protection effect of the novel coronavirus RBD nanoparticle vaccine is obviously improved.

The invention provides application of D-mannose in preparation of a product for improving intestinal mucosa immunity and / or intestinal flora homeostasis of weaned piglets, and particularly belongs to the technical field of weaned piglet breeding. The invention provides application of D-mannose in preparation of a product for improving intestinal mucosal immunity and / or intestinal flora homeostasis of weaned piglets. The D-mannose is derived from a natural plant, can stably and efficiently improve intestinal mucosa immunity and intestinal flora homeostasis of the weaned piglets, relieves diarrhea, and improves the growth performance of the weaned piglets at the same time. Specifically, D-mannose can improve the growth performance of weaned piglets, reduce the diarrhea rate, improve the intestinal structure, enhance the chemical barrier function of the intestinal tract, reduce the abundance of harmful bacteria in the intestinal tract and increase the content of short-chain fatty acid producing bacteria.

The invention belongs to the technical field of gene engineering, and particularly relates to recombinant lactobacillus for expressing clostridium perfringens multiple antigens of targeted dendritic cells as well as a construction method and application of the recombinant lactobacillus. The recombinant lactobacillus contains an expression vector for expressing a fusion gene; the fusion gene comprises sequences for coding and expressing a PgsA '-fimA fusion protein, a LysM-Fba fusion protein, an LP1261-NetB fusion protein, a phi54 targeting element and a Pas escape element; a sequence for coding the PgsA '-fimA fusion protein is shown as SEQ ID NO: 1, a sequence for coding the LysM-Fba fusion protein is shown as SEQ ID NO: 2, and a sequence for coding the LP1261-NetB fusion protein is shown as SEQ ID NO: 3. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunocompetence of organisms can be comprehensively enhanced, and the recombinant lactobacillus can be used for preparing oral vaccines for prevention and control of chicken necrotic enteritis.

The invention relates to the field of veterinary biological products, in particular to a porcine epidemic diarrhea virus attenuated strain and a vaccine and application thereof. The porcine epidemic diarrhea virus attenuated strain provided by the invention is obtained through in-vitro separation culture and continuous five rounds of plaque purification and screening technology, and has stable culture characteristics. Meanwhile, the virulence of the strain on newborn piglets and weaned piglets is remarkably reduced, and the virulence does not have the phenomenon of reversion after continuous passage for five times in a pig body. The strain has good immunogenicity, and mucosal immunity and systemic immune response of an organism can be activated at the same time by adopting an oral immunization mode. A neutralizing antibody of 1: 8-1: 16 can be detected in oral fluid and serum after the piglets are immunized for 14 days, and a large amount of sIgA is generated in milk after the pregnant sows are immunized, so that the piglets obtain effective passive immune protection.

The attenuated strain of Bordetella bronchiseptica (YZ01-P strain) of the present invention is genetically homologous to the pathogenic Bordetella bronchiseptica prevalent in China. After immunizing animals with the vaccine composition prepared from the attenuated strain, it can induce the animal body to rapidly produce good mucosal immunity, and its immunological efficacy can be maintained for a long time. During the period of maintaining immunological efficacy, it can effectively prevent the occurrence of canine infectious respiratory diseases caused by infection with virulent strains of Bordetella bronchiseptica. At the same time, it can also be reasonably inferred that it can greatly reduce the occurrence of canine infectious diseases characterized by respiratory diseases caused by the mixed infection of virulent strains of Bordetella bronchiseptica with canine distemper, canine parainfluenza and canine adenovirus.

The invention belongs to the technical field of genetically engineered bacteria, and particularly discloses an African swine fever oral vaccine saccharomyces cerevisiae engineered bacterium as well as a construction method and application thereof. A free plasmid system is adopted to transform saccharomyces cerevisiae, and an engineering strain for displaying ASFV p30 / p54 antigens is constructed. The matched plasmid system has the advantages of being simple and convenient to operate and short in construction period, construction and transformation of recombinant plasmids can be completed in a short time, and the research and development efficiency of vaccine candidate strains is remarkably improved. Meanwhile, the free plasmid can be stably inherited and copied in a yeast host, so that the expression stability of a target antigen in a passage process is guaranteed, and large-scale fermentation preparation is facilitated. After oral immunization, the saccharomyces cerevisiae engineering bacterium constructs a system-mucous membrane dual defense barrier in a tested animal pig body, not only induces high-level system IgG, but also induces remarkable sIgA mucous membrane immunity in intestinal tracts, and provides a new idea and technical reserve for research and development of ASFV subunit vaccines.

The application provides a lactic acid bacteria expressing an African swine fever virus fusion antigen and an application thereof. The lactic acid bacteria are integrated with a fusion gene, the fusion gene comprising a gene encoding an OprI protein and at least one gene selected from genes encoding a PP62 protein, an MGF505-3R protein, an EP364R protein, a K145R protein and a DP96R protein, and a starting strain of the lactic acid bacteria is Lactobacillus plantarum. Using the lactic acid bacteria to immunize animals can induce mucosal immunity, cellular immunity and humoral immunity responses, and comprehensively enhance the immune capacity of the body, and the lactic acid bacteria can be used for preparing an oral vaccine for the prevention and control of African swine fever.

One aspect of the present invention provides: a vector including a gene encoding a non-structural alphavirus protein of and a gene encoding a target protein; a cell infected with the vector; a virus-like particle (VLP); and a vaccine composition comprising same. The vector is a single-vector system and can easily and conveniently produce VLP containing saRNA without a helper vector. The VLP and vaccine composition produced through the vector produce a sufficient amount of antibody from only a single administration, have excellent safety due to the absence of additional proliferation, can be administered to mucous membranes, and induces mucous membrane immunity, and thus exhibits a remarkably superior respiratory disease prevention or treatment effect compared to therapeutic agents for intramuscular administration.

The invention belongs to the technical field of health-care products, and discloses an oligosaccharide selenium ganoderma lucidum capsule for enhancing immunity and inhibiting tumors and a preparation method, and the content of the capsule is prepared from the following raw materials in parts by mass: 150-160 parts of collagen, 80-85 parts of chitosan oligosaccharide, 110-130 parts of ganoderma lucidum extract, 45-55 parts of selenium-enriched yeast, 50-80 parts of maltodextrin and 7-10 parts of magnesium stearate. The skin barrier can be improved, intercellular communication can be promoted and local immune response can be stimulated through low-molecular peptide of collagen, intestinal flora balance can be adjusted through chitosan oligosaccharide, probiotic growth can be promoted, mucous membrane immunity can be further improved, and finally immune cells can be effectively activated through polysaccharide and triterpenoids in the ganoderma lucidum extract, so that the immunity of a human body is improved. The activity of macrophages and natural killer cells is enhanced, and the multi-target and multi-path immune regulation effect can effectively enhance the defense of the body to pathogenic microorganisms.

The invention discloses a composition for preventing and treating oral diseases or conditions, a preparation method and application thereof. The external vesicles based on oral pathogenic bacteria are rich in nano-scale vesicles of immune activation and defense factors aiming at periodontitis, and after the external vesicles enter a body through oral mucosa administration, the external vesicles are passively targeted into lymph nodes related to the oral mucosa to induce mucosa immune specific antibody expression, so that the immune defense capacity to the pathogenic bacteria is improved. Preferably, a calcium phosphate shell is coated outside the oral bacterial outer vesicle, and the calcium phosphate shell can only be dissolved under an acidic condition, so that the engineered vesicle can be degraded after targeting to lymph nodes and being phagocytosed into dendritic cell lysosome, and the inflammatory reaction of a drug delivery area is avoided. The administration form of the sublingual disintegrating tablet can improve the bioavailability of the vaccine while local mucosal administration activates mucosal immunity, and the convenient administration form is also beneficial to the promotion and popularization of the periodontitis vaccine in clinical chair-side diagnosis and treatment or grassroots communities.

The invention relates to the technical field of medicines, and provides a construction method and application of a smog-induced IgA nephropathy mouse model. An IgAN model based on PM2.5 continuous exposure induction is constructed, the influence of long-term environmental particulate matter stimulation on respiratory mucosal immunity can be simulated, and a key chain of mucosal immune activate-Gd-IgA1 overexpression-immune complex formation in human IgAN is effectively simulated, so that the correlation between kidney phenotypic change and mucosal immune activation is observed, and the accuracy and the sensitivity of the kidney phenotypic change are improved. And evidence is provided for direct association of the mucous membrane system and the renal injury. The model better conforms to the human pathogenesis background, the phenotype is stable, the operation is controllable, and conversion or popularization is facilitated.

The invention relates to the technical field of medicines, in particular to a zinc ion polypeptide compound immunologic adjuvant as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing polypeptide, a PBS buffer solution, new coronavirus S protein, a CpG ODN immune activator and zinc ions, and standing to obtain the zinc ion polypeptide compound immunologic adjuvant. A dual-adjuvant system mixed with CpG ODN shows excellent performance in activation of lung tissue immunity, and in the cellular immunity level, the response intensity of CD4 + T and CD8 + T cells is enhanced, and formation of related tissue resident memory T cell phenotypes is promoted; on the humoral immunity level, a Gel (Zn < 2 + >) and CpG ODN dual-adjuvant system obviously stimulates the increase of the number of B cells and the activation, and can effectively stimulate the secretion of a main antibody sIgA for mucosal immunity. On the whole, the dual adjuvants realize the synergistic enhancement of T cell (containing TRM) and B cell immunity.

Provided are a composition for preventing and treating an oral disease or condition, a preparation method therefor, and the use thereof. The composition comprises extracellular vesicles derived from oral pathogenic bacteria. The extracellular vesicles are nanoscale vesicles rich in immune activation and defensive factors against pathogenic bacterial infection. Upon administration via the oral mucosa into a body, the vesicles are passively aimed at lymph nodes associated with the oral mucosa to induce the expression of a mucosal immunity-specific antibody, thereby enhancing immune defense against pathogenic bacteria. The extracellular vesicles of oral pathogenic bacteria are coated with a calcium phosphate shell, and the shell is soluble only under acidic conditions and degrades only after the extracellular vesicles are aimed at the lymph nodes and are phagocytosed into lysosomes of dendritic cells, thereby avoiding inflammatory reactions in an administration area. By using a sublingual disintegrating tablet as the form of administration, the bioavailability of a vaccine can be enhanced while achieving the local administration at the mucosa and activating mucosal immunity. Moreover, the composition is convenient to administer, which is conducive to the diagnosis and treatment of oral bacterial infectious diseases.

The invention relates to the technical field of molecular biology, and particularly discloses a preparation method and application of universal influenza virus nasal spray subunit vaccine candidate protein, and the preparation method comprises the following preparation steps: synthesis of a recombinant plasmid pET-28a-FluA; the preparation method comprises the following steps: carrying out transformation induction on a recombinant plasmid pET-28a-FluA to prepare a recombinant protein; purifying the recombinant protein to obtain a target protein; preparing a chitosan solution, and emulsifying the chitosan solution and a target protein to obtain a universal influenza virus nasal spray subunit vaccine candidate protein; according to the invention, a plurality of epitopes with good immunogenicity and conservative property are connected in series through bioinformatics prediction to construct the recombinant protein, and meanwhile, the protective capability and the protective range of the recombinant protein are increased to the greatest extent by utilizing the enhancement effect of an intramolecular adjuvant flagellin on mucosal immunity; compared with a traditional subunit vaccine, the subunit vaccine has better immunogenicity and a wider protection effect.

The application specifically discloses a kind of nanovaccine for thrombosis prevention and its preparation method and application, it is related to thrombotic disease, especially related to the nanovaccine for treating thrombotic disease.The nanovaccine provided by the application has good immunogenicity without macromolecular heterologous protein carrier such as KLH;The process simplicity and repeatability are improved by reducing complex chemical coupling and purification steps;The dependence on traditional high-stimulating immune adjuvant is reduced, and the biological safety is improved;The stability of antigen in gastrointestinal environment is significantly improved;Active targeting delivery of M cells and dendritic cells is realized;Dendritic cell maturation and antigen presentation are promoted, and mucosal immunity and systemic immunity level are improved;The advantages such as effectively inhibiting thrombosis are realized, and a new type of oral antithrombotic vaccine system with high compliance suitable for long-term thrombosis prevention is constructed.

The present invention relates to a vaccine composition for mucosal immunity and use thereof. It has been identified that the vaccine composition of the present invention is in the form of a 2D patch and effectively induces nasal mucosal immunity despite nasal mucociliary clearance (MCC). Thus, the vaccine composition provided in the present invention can be variously utilized for mucosal immunity in which various antigenic substances are used.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant lactobacillus plantarum for preventing and controlling chicken necrotic enteritis as well as a preparation method and application of the recombinant lactobacillus plantarum. The invention provides an oral vaccine vector capable of co-expressing various key virulence factor antigens (FimB, NetB, CnaA and FBA) of clostridium perfringens, and by fusing dendritic cell (DC) targeting molecules (nano antibody Phi74), the efficiency of recognizing and taking in the vaccine vector by full-time antigen presenting cells is remarkably improved, so that the immunogenicity is enhanced. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunity of organisms is comprehensively enhanced, and a safe and efficient oral immunization scheme suitable for large-scale breeding is established for treating chicken necrotic enteritis.

Disclosed in the present invention are a fatty acid-modified coronavirus antigen and use thereof, pertaining to the field of biomedicine. The fatty acid-modified coronavirus antigen comprises a fatty acid-modified N-terminal cysteine (Cys) and a coronavirus antigen, and may comprise a linking domain. The coronavirus antigen is a coronavirus spike protein (S protein) receptor-binding domain (RBD). The fatty acid-modified coronavirus S protein RBD can self-assemble into nanoparticles. Compared with an RBD without fatty acid modification, the antigen can induce faster and higher humoral immunity by means of injection immunization, and can also induce mucosal immunity and humoral immunity by means of respiratory nebulization immunization, making it a candidate mucosal vaccine with potential medical value.

The invention relates to the technical field of mucosal immunity and immunogenicity collaborative optimization, in particular to a preparation method of a mucosal immune type mycoplasma bovis live vector vaccine, attenuated mycoplasma bovis is used as a vector, an inducer X containing an FRET modified nucleic acid aptamer is combined with CRISPR-Cas12a for modification, a virulence gene is knocked out, and a mucosal targeting gene fused with CTB is inserted; carrying out deep codon optimization on the antigen gene, fusing the antigen gene with the glycosylation immunopotentiation peptide, and carrying out novel enzyme digestion connection to construct a recombinant vector; and intelligently fermenting in an improved culture medium, centrifuging, resuspending by using a special protective agent, and freeze-drying to obtain the vaccine. According to the preparation method, the mucous membrane targeting and immunogenicity of the vaccine are improved, and the production process is optimized; mucosal immunity can be quickly stimulated, various immune reactions are activated, the vaccine activity and quality are guaranteed, and the mycoplasmosis bovis is efficiently prevented.

The application discloses a mucosal immunity enhanced recombinant lactobacillus expressing PEDV S1 protein and a construction method and application thereof. The mucosal immunity enhanced recombinant lactobacillus contains a recombinant lactic acid bacteria expression vector expressing the PEDV S1 protein, wherein the PEDV S1 protein is fused with an M cell targeting peptide (Col) and a dendritic cell targeting peptide (6aa) at an amino acid end, and is fused with a mucosal immunity adjuvant (LTB) at a carboxyl end; and the connection sequence of each part is Col-6aa-S1-LTB. The mucosal immunity enhanced recombinant lactobacillus constructed by the application significantly improves the mucosal immunity response efficiency (including intestinal mucus SIgA and serum IgG levels) of the PEDV S1 antigen through the synergistic effect of the targeting peptide (DC / MC targeting peptide) and the adjuvant (LTB), and can significantly induce humoral immunity, cellular immunity and mucosal immunity response of pregnant animals and produce maternal antibodies, improves the intestinal SIgA level of newborn animals, and provides an effective technical means for the prevention and treatment of PED.